$CPIX
CUMBERLAND PHARMACEUTICALS INC

2014 Q4 Form 10-Q Financial Statement

#000144530514004964 Filed on November 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $9.329M $9.729M $8.160M
YoY Change 14.34% 49.02% -40.42%
Cost Of Revenue $1.360M $1.340M $2.150M
YoY Change -36.74% 29.95% -0.92%
Gross Profit $7.970M $8.389M $6.010M
YoY Change 32.61% 52.6% -47.83%
Gross Profit Margin 85.43% 86.23% 73.65%
Selling, General & Admin $5.740M $5.980M $6.860M
YoY Change -16.33% 11.38% -10.79%
% of Gross Profit 72.02% 71.28% 114.14%
Research & Development $770.0K $934.8K $1.340M
YoY Change -42.54% -35.11% 204.55%
% of Gross Profit 9.66% 11.14% 22.3%
Depreciation & Amortization $610.0K $580.0K $380.0K
YoY Change 60.53% 87.1% 58.33%
% of Gross Profit 7.65% 6.91% 6.32%
Operating Expenses $7.020M $6.915M $8.480M
YoY Change -17.22% 1.55% 2.54%
Operating Profit $946.1K $989.0K -$2.472M
YoY Change -138.27% -165.29% -175.99%
Interest Expense $30.00K $26.88K $30.00K
YoY Change 0.0% 10.67% 0.0%
% of Operating Profit 3.17% 2.72%
Other Income/Expense, Net
YoY Change
Pretax Income $980.0K $1.070M -$2.440M
YoY Change -140.16% -170.47% -174.16%
Income Tax $330.0K $341.0K -$930.0K
% Of Pretax Income 33.67% 31.86%
Net Earnings $668.9K $745.9K -$1.500M
YoY Change -144.58% -190.97% -183.1%
Net Earnings / Revenue 7.17% 7.67% -18.39%
Basic Earnings Per Share $0.04 $0.04 -$0.08
Diluted Earnings Per Share $0.04 $0.04 -$0.08
COMMON SHARES
Basic Shares Outstanding 17.36M shares 17.54M shares 18.11M shares
Diluted Shares Outstanding 17.85M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.71M $54.28M $54.89M
YoY Change -0.33% -16.72% -22.73%
Cash & Equivalents $39.87M $39.64M $40.87M
Short-Term Investments $14.84M $14.63M $14.02M
Other Short-Term Assets $5.002M $4.445M $3.537M
YoY Change 41.42% 28.25% -10.7%
Inventory $5.600M $6.131M $5.723M
Prepaid Expenses
Receivables $5.505M $5.296M $4.530M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $70.81M $70.15M $68.68M
YoY Change 3.11% -10.37% -21.27%
LONG-TERM ASSETS
Property, Plant & Equipment $651.0K $731.1K $880.6K
YoY Change -26.07% -25.01% -25.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.792M $3.025M $1.346M
YoY Change 33.17% 111.56% 108.51%
Total Long-Term Assets $24.59M $23.75M $18.93M
YoY Change 29.87% 74.14% 66.65%
TOTAL ASSETS
Total Short-Term Assets $70.81M $70.15M $68.68M
Total Long-Term Assets $24.59M $23.75M $18.93M
Total Assets $95.41M $93.90M $87.61M
YoY Change 8.89% 2.17% -11.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.243M $3.205M $2.036M
YoY Change 59.28% 41.07% -27.04%
Accrued Expenses $10.51M $5.510M
YoY Change 90.69% 4.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.75M $12.16M $7.546M
YoY Change 82.21% 124.61% -6.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $902.8K $900.0K $776.1K
YoY Change 16.33% 28.57% 26.83%
Total Long-Term Liabilities $902.8K $900.0K $776.1K
YoY Change 16.33% -83.93% 26.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.75M $12.16M $7.546M
Total Long-Term Liabilities $902.8K $900.0K $776.1K
Total Liabilities $14.65M $13.02M $8.322M
YoY Change 76.07% 18.58% -36.12%
SHAREHOLDERS EQUITY
Retained Earnings $18.82M $18.15M $16.39M
YoY Change 14.78% 1.42% -11.38%
Common Stock $61.94M $62.95M $63.07M
YoY Change -1.79% -0.39% -6.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.76M $81.10M $79.47M
YoY Change
Total Liabilities & Shareholders Equity $95.41M $93.90M $87.61M
YoY Change 8.89% 2.17% -11.14%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income $668.9K $745.9K -$1.500M
YoY Change -144.58% -190.97% -183.1%
Depreciation, Depletion And Amortization $610.0K $580.0K $380.0K
YoY Change 60.53% 87.1% 58.33%
Cash From Operating Activities $2.730M $2.140M -$190.0K
YoY Change -1536.84% -351.76% -109.55%
INVESTING ACTIVITIES
Capital Expenditures -$1.490M -$990.0K -$4.870M
YoY Change -69.4% 25.32% 673.02%
Acquisitions
YoY Change
Other Investing Activities -$20.00K $240.0K $5.100M
YoY Change -100.39% -14.29% 180.22%
Cash From Investing Activities -$1.510M -$750.0K $240.0K
YoY Change -729.17% 44.23% -79.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000M -790.0K -5.180M
YoY Change -80.69% -65.35% -1538.89%
NET CHANGE
Cash From Operating Activities 2.730M 2.140M -190.0K
Cash From Investing Activities -1.510M -750.0K 240.0K
Cash From Financing Activities -1.000M -790.0K -5.180M
Net Change In Cash 220.0K 600.0K -5.130M
YoY Change -104.29% -116.44% -244.92%
FREE CASH FLOW
Cash From Operating Activities $2.730M $2.140M -$190.0K
Capital Expenditures -$1.490M -$990.0K -$4.870M
Free Cash Flow $4.220M $3.130M $4.680M
YoY Change -9.83% -5316.67% 78.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
cpix Increase Decrease In Current Operating Liabilities
IncreaseDecreaseInCurrentOperatingLiabilities
-2942455 USD
cpix Increase Decrease In Current Operating Liabilities
IncreaseDecreaseInCurrentOperatingLiabilities
2293818 USD
CY2014Q1 cpix Inventory Extended Shelf Life
InventoryExtendedShelfLife
P6Y
CY2014Q1 cpix Inventory Shelf Life
InventoryShelfLife
P5Y
CY2014Q2 cpix Loans Forgivenin Exchange For Share Issued Amount
LoansForgiveninExchangeForShareIssuedAmount
2400000 USD
cpix Numberof Product Lines Acquired
NumberofProductLinesAcquired
2 product_line
CY2014Q3 cpix Other Long Term Obligations Excluding Current Portion
OtherLongTermObligationsExcludingCurrentPortion
863356 USD
CY2013Q4 cpix Other Long Term Obligations Excluding Current Portion
OtherLongTermObligationsExcludingCurrentPortion
776125 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3205233 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2035853 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5296114 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4530424 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12038 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12038 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
202982 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
610677 USD
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
485493 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1083706 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
554279 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
187248 shares
CY2013Q4 us-gaap Assets
Assets
87613738 USD
CY2014Q3 us-gaap Assets
Assets
93904132 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
68679715 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-604251 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
70149972 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40869457 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39644081 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54349381 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46011203 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8338178 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1225376 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2014Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17985503 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17423825 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17985503 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17423825 shares
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
63073941 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
62953489 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1713902 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-640023 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
729184 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-832495 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
35772 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
12553 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
40908 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
16736 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
745920 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1754810 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-819942 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3692256 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1030943 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1339723 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3294411 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
8740009 USD
us-gaap Costs And Expenses
CostsAndExpenses
24959761 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
8043343 USD
us-gaap Costs And Expenses
CostsAndExpenses
25197056 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-36255 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-76332 USD
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
47400000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
917012 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1383611 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1077099 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-511908 USD
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1077099 USD
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
-511908 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15498819 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19997795 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2158057 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1958629 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6195523 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6389569 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1230273 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2766232 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1070166 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1518704 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
340982 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1052330 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-590250 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-686209 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1822786 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
765689 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-782742 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1002160 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
112737 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
105416 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1354793 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
177754 USD
us-gaap Interest Expense
InterestExpense
62721 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
24286 USD
us-gaap Interest Expense
InterestExpense
51358 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
26877 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3697862 USD
CY2014Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3475936 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
5722882 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
6130722 USD
CY2014Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2654786 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2025020 USD
CY2014Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3400000 USD
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3500000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
204892 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
20350 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
108005 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
161709 USD
CY2013Q4 us-gaap Liabilities
Liabilities
8321895 USD
CY2014Q3 us-gaap Liabilities
Liabilities
13018839 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93904132 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87613738 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7545770 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12155483 USD
us-gaap Proceeds From Sale Of Interest In Corporate Unit
ProceedsFromSaleOfInterestInCorporateUnit
0 USD
us-gaap Proceeds From Sale Of Interest In Corporate Unit
ProceedsFromSaleOfInterestInCorporateUnit
1000005 USD
CY2014Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
0 USD
CY2013Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
0 USD
CY2014Q3 us-gaap Marketable Securities
MarketableSecurities
14634302 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5305303 USD
CY2013Q4 us-gaap Marketable Securities
MarketableSecurities
14019761 USD
CY2013Q4 us-gaap Minority Interest
MinorityInterest
-176638 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3957854 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
938761 USD
us-gaap Net Income Loss
NetIncomeLoss
-604251 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3971636 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4521429 USD
CY2014Q3 us-gaap Minority Interest
MinorityInterest
-217546 USD
CY2014Q1 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
0.85
CY2014Q2 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
0.80
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-661801 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-819942 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
745920 USD
us-gaap Net Income Loss
NetIncomeLoss
1754810 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-40908 USD
CY2013Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-12553 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-35772 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-16736 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
230522 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
974809 USD
us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
1000005 USD
CY2014Q2 us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
1000000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1514768 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1329261 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
2612698 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
989038 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3537191 USD
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4444753 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3025236 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2554557 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5509917 USD
CY2014Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8950250 USD
us-gaap Payments For Previous Acquisition
PaymentsForPreviousAcquisition
2000000 USD
us-gaap Payments For Previous Acquisition
PaymentsForPreviousAcquisition
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3918436 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2738905 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2600266 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1617874 USD
CY2014Q2 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
1000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
-41292 USD
us-gaap Profit Loss
ProfitLoss
1713902 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-832495 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3754903 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92435 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
150387 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
500000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3001735 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1758906 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4371508 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
729184 USD
us-gaap Profit Loss
ProfitLoss
-640023 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
880647 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
731129 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
934783 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2622310 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1440584 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4276206 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
18149350 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
16394540 USD
us-gaap Sales Revenue Net
SalesRevenueNet
27572459 USD
us-gaap Sales Revenue Net
SalesRevenueNet
23867795 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
6528575 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
9729047 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11365966 USD
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3410205 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10626193 USD
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3821953 USD
us-gaap Share Based Compensation
ShareBasedCompensation
542118 USD
us-gaap Share Based Compensation
ShareBasedCompensation
480806 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
541349 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1077099 USD
CY2013Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
10000000.0 USD
CY2010Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
10000000.0 USD
CY2011Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
10000000.0 USD
CY2012Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
10000000.0 USD
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2738905 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
81102839 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
79468481 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80885293 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
79291843 USD
CY2014Q3 us-gaap Trading Securities
TradingSecurities
14634302 USD
CY2013Q4 us-gaap Trading Securities
TradingSecurities
14019761 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-135296 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-138627 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) the projection of future taxable income for the realization of deferred tax assets.</font></div></div>
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
303205 shares
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
259846 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18420465 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17990561 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18233407 shares
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17358071 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17848110 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18420465 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17730715 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18233407 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17544905 shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001087294
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
CUMBERLAND PHARMACEUTICALS INC

Files In Submission

Name View Source Status
0001445305-14-004964-index-headers.html Edgar Link pending
0001445305-14-004964-index.html Edgar Link pending
0001445305-14-004964.txt Edgar Link pending
0001445305-14-004964-xbrl.zip Edgar Link pending
cpix-20140930.xml Edgar Link completed
cpix-20140930.xsd Edgar Link pending
cpix-20140930_cal.xml Edgar Link unprocessable
cpix-20140930_def.xml Edgar Link unprocessable
cpix-20140930_lab.xml Edgar Link unprocessable
cpix-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
q32014-exhibit311.htm Edgar Link pending
q32014-exhibit312.htm Edgar Link pending
q32014-exhibit321.htm Edgar Link pending
q3201410q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending